ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0208

Unlocking COVID-19 Vaccination Choices in Rheumatoid Arthritis: Insights from a Monocentric Study

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0581

Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry

SpA Including PsA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0127

Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0394

Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0348

Upadacitinib in Interstitial Lung Disease Associated with Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0206

Urate Lowering Therapy to Acute Treatment Ratio (ULTrA) Index – a Novel Quality Indicator Associated with Reduced Hospital Admissions for Gout

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0649

Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0425

Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0489

Use of Chair Sit-to-Stand as a Pragmatic Alternative to Assess Frailty in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0435

Use of Contraception in Women of Childbearing Age with Immune-Mediated Rheumatic Diseases: Experience from an Italian Centre

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0742

Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteritis on Tocilizumab

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0201

Use of Infrared Thermography for Expedited Rheumatology Referral in a Primary Care Center

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0503

Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0456

Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0134

Use of Oral Contraceptives in Females with Rheumatoid Arthritis Is Not Associated with an Increased Risk of Venous Thromboembolism: United Kingdom-population Based Study

Epidemiology & Public Health Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].